HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Signature of VDR miRNAs and epigenetic modulation of vitamin D signaling in melanoma cell lines.

AbstractBACKGROUND:
Melanoma cells express the nuclear vitamin D receptor (VDR), indicating that malignant melanoma represents a promising target for treatment with 1,25-dihydroxyvitamin D3 (1,25(OH)(2)D(3)) or its analogs. We previously showed that some melanoma cell lines are resistant to the antiproliferative effects of 1,25(OH)(2)D(3) and that 1,25(OH)(2)D(3)-sensitivity can, at least in part, be restored by co-treatment with the histone deacetylase inhibitor (HDACI) Trichostatin A (TSA) or with the DNA methyltransferase inhibitor (DNMTI), 5-azacytidine (5-Aza). This study aimed at gaining further insights into the molecular mechanisms that underlie the epigenetic modulation of 1,25(OH)(2)D(3)-sensitivity in melanoma cells.
MATERIALS AND METHODS:
The expression of VDR mRNA, protein and two candidates of VDR microRNAs (miR-125b, miR-27b) were compared in 1,25(OH)(2)D(3)-responsive (MeWo, SK-Mel28) and -resistant (SK-Mel5, IGR) melanoma cell lines and in normal human melanocytes (NHM) using real time PCR and western blot analysis. Additionally, the effect of 1,25(OH)(2)D(3), epigenetic modulating drugs (TSA, 5-Aza) and miR-125b antisense on the expression of VDR messenger RNA (mRNA)/protein, miR-125b and miR-27b was investigated.
RESULTS:
Treatment with 1,25(OH)(2)D(3) and/or epigenetic drugs (5-Aza, TSA) modulated the VDR mRNA expression in the 1,25(OH)(2)D(3)-responsive and - resistant melanoma cell lines and in the NHM. Treatment with 5-Aza, but not with TSA, reduced the expression of miR-125b in the 1,25(OH)(2)D(3)-responsive and -resistant melanoma cell lines and in the NHM. Treatment with 1,25(OH)(2)D(3) and/or epigenetic drugs (5-Aza, TSA) reduced the miR-27b expression in three out of four melanoma cell lines. Moreover, no difference was observed in VDR protein expression in the 1,25(OH)(2)D(3)-responsive as compared to the 1,25(OH)(2)D(3)-resistant melanoma cell lines. Transfection with miR-125b antisense did not affect the VDR mRNA/protein expression in the IGR cells.
CONCLUSION:
Responsiveness to 1,25(OH)(2)D(3) corresponds to the expression level of VDR mRNA which in turn might be regulated by VDR microRNAs or epigenetic modulating drugs.
AuthorsSalma Essa, Sandra Reichrath, Ulrich Mahlknecht, Mathias Montenarh, Thomas Vogt, Jörg Reichrath
JournalAnticancer research (Anticancer Res) Vol. 32 Issue 1 Pg. 383-9 (Jan 2012) ISSN: 1791-7530 [Electronic] Greece
PMID22213330 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antimetabolites, Antineoplastic
  • MIRN125 microRNA, human
  • MIRN27 microRNA, human
  • MicroRNAs
  • RNA, Messenger
  • Receptors, Calcitriol
  • dihydroxy-vitamin D3
  • Vitamin D
  • Azacitidine
Topics
  • Antimetabolites, Antineoplastic (pharmacology)
  • Apoptosis (drug effects)
  • Azacitidine (pharmacology)
  • Blotting, Western
  • Cell Proliferation (drug effects)
  • Cells, Cultured
  • Epigenomics
  • Humans
  • Melanocytes (cytology, drug effects, metabolism)
  • Melanoma (drug therapy, genetics, metabolism)
  • MicroRNAs (genetics)
  • RNA, Messenger (genetics)
  • Real-Time Polymerase Chain Reaction
  • Receptors, Calcitriol (genetics, metabolism)
  • Skin Neoplasms (drug therapy, genetics, metabolism)
  • Vitamin D (analogs & derivatives, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: